Filtered By:
Condition: Arthritis
Drug: Abatacept

This page shows you your search results in order of date.

Order by Relevance | Date

Total 29 results found since Jan 2013.

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years ’ experience of a tertiary pediatric rheumatology center
In this study, drug side effects in patients who were followed up with a rheumatic disease and treated with parenteral administration methods were evaluated. The drug side effects in children who were followed up with a rheumatic disease and treated with parenteral treatments between 2010 and 2019 were recorded, retrospectively. All parenteral treatments are applied by a clinical nurse specialist (CNS) who is experienced in pediatric rheumatology for 10 years. Four hundred and thirteen patients were evaluated in this study. The mean age was 12.09  ± 5.05 years. Most of them were diagnosed with juvenile idiopathic art...
Source: Rheumatology International - December 20, 2019 Category: Rheumatology Source Type: research

Safety of Abatacept Compared With Other DMARDs in RA Safety of Abatacept Compared With Other DMARDs in RA
Find out how the safety profile for abatacept compared with that of other DMARDs for rheumatoid arthritis.Arthritis Research & Therapy
Source: Medscape Allergy Headlines - August 16, 2019 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news

Memory B Cells and Response to Abatacept in Rheumatoid Arthritis
In conclusion, and although these data need to be confirmed in an independent cohort, our data support a role for memory B cells in the mechanism of action of abatacept in RA.
Source: Clinical Reviews in Allergy and Immunology - May 5, 2017 Category: Allergy & Immunology Source Type: research

Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis
Conclusions In RA, incidence of DM is increased. Hydroxychloroquine and abatacept were associated with decreased risk of DM, and glucocorticoids and statins with increased risk.
Source: Annals of the Rheumatic Diseases - April 6, 2017 Category: Rheumatology Authors: Ozen, G., Pedro, S., Holmqvist, M. E., Avery, M., Wolfe, F., Michaud, K. Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
Conclusions This large European collaborative project did not confirm an overall increased risk of melanoma following exposure to TNFi.
Source: Annals of the Rheumatic Diseases - January 9, 2017 Category: Rheumatology Authors: Mercer, L. K., Askling, J., Raaschou, P., Dixon, W. G., Dreyer, L., Hetland, M. L., Strangfeld, A., Zink, A., Mariette, X., Finckh, A., Canhao, H., Iannone, F., Zavada, J., Morel, J., Gottenberg, J.-E., Hyrich, K. L., Listing, J. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Immunosuppressive Activity of Abatacept on Circulating T Helper Lymphocytes from Juvenile Idiopathic Arthritis Patients
Conclusions: Abatacept in vitro inhibits proliferation and cytokine production in healthy donors, and reduces parameters of inflammation in vivo in JIA patients. The reduction of the proliferative response to recall antigens induced by abatacept was evident only soon after drug administration, suggesting that its immunosuppressive activity is maintained only for a short time.Int Arch Allergy Immunol 2016;171:45-53
Source: International Archives of Allergy and Immunology - November 7, 2016 Category: Allergy & Immunology Source Type: research

Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study
Conclusions In this first international prospective study, the composite PDUS score is responsive to abatacept. GLOESS demonstrated the rapid onset of action of abatacept, regardless of the number of joints examined. Ultrasound is an objective tool to monitor patients with RA under treatment. Trial registration number NCT00767325.
Source: Annals of the Rheumatic Diseases - September 8, 2016 Category: Rheumatology Authors: D'Agostino, M.-A., Wakefield, R. J., Berner-Hammer, H., Vittecoq, O., Filippou, G., Balint, P., Möller, I., Iagnocco, A., Naredo, E., Ostergaard, M., Boers, M., Gaillez, C., Van Holder, K., Le Bars, M., on behalf of the OMERACT-EULAR-Ultrasound Ta Tags: Open access, Immunology (including allergy), Radiology, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Clinical diagnostic tests, Radiology (diagnostics) Clinical and epidemiological research Source Type: research

Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis
Discussion Findings from this observational study of patients with RA suggested that anti-TNF biologics may be associated with higher AMI risk compared with abatacept.
Source: Annals of the Rheumatic Diseases - September 8, 2016 Category: Rheumatology Authors: Zhang, J., Xie, F., Yun, H., Chen, L., Muntner, P., Levitan, E. B., Safford, M. M., Kent, S. T., Osterman, M. T., Lewis, J. D., Saag, K., Singh, J. A., Curtis, J. R. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
Conclusions The rate of zoster associated with tofacitinib was approximately double that observed in patients using biologics.
Source: Annals of the Rheumatic Diseases - September 8, 2016 Category: Rheumatology Authors: Curtis, J. R., Xie, F., Yun, H., Bernatsky, S., Winthrop, K. L. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
Conclusions Structural benefits with ABA/MTX or ABA may be maintained 6 months after withdrawal of all treatments in patients who have achieved remission or low disease activity. Trial registration number NCT01142726; Results.
Source: Annals of the Rheumatic Diseases - July 7, 2016 Category: Rheumatology Authors: Peterfy, C., Burmester, G. R., Bykerk, V. P., Combe, B. G., DiCarlo, J. C., Furst, D. E., Huizinga, T. W. J., Wong, D. A., Conaghan, P. G., Emery, P. Tags: Open access, Immunology (including allergy), Bone and joint infections, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Calcium and bone Clinical and epidemiological research Source Type: research

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching
Conclusions We compared patients treated with abatacept or tocilizumab after statistical adjustment by propensity score matching. Clinical efficacies, including SDAI, were comparable in both treatment groups. However, the predictive factors were different: abatacept appears to benefit patients with higher RF titres, and early induction of tocilizumab is an important factor for good clinical efficacy.
Source: Annals of the Rheumatic Diseases - June 9, 2016 Category: Rheumatology Authors: Kubo, S., Nakayamada, S., Nakano, K., Hirata, S., Fukuyo, S., Miyagawa, I., Hanami, K., Saito, K., Tanaka, Y. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry
Conclusions In common practice, patients treated with ABA had more comorbidities than in clinical trials and serious infections were slightly more frequently observed. In the ORA registry, predictive risk factors of serious infections include age and history of serious infections.
Source: Annals of the Rheumatic Diseases - May 9, 2016 Category: Rheumatology Authors: Salmon, J. H., Gottenberg, J. E., Ravaud, P., Cantagrel, A., Combe, B., Flipo, R. M., Schaeverbeke, T., Houvenagel, E., Gaudin, P., Loeuille, D., Rist, S., Dougados, M., Sibilia, J., Le Loët, X., Meyer, O., Solau-Gervais, E., Marcelli, C., Bardin, Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial
Conclusions In AMPLE, baseline anti-CCP2 positivity was associated with a better response for abatacept and adalimumab. Patients with the highest baseline anti-CCP2 antibody concentrations had better clinical response with abatacept than patients with lower concentrations, an association that was not observed with adalimumab. Trial registration number NCT00929864.
Source: Annals of the Rheumatic Diseases - March 10, 2016 Category: Rheumatology Authors: Sokolove, J., Schiff, M., Fleischmann, R., Weinblatt, M. E., Connolly, S. E., Johnsen, A., Zhu, J., Maldonado, M. A., Patel, S., Robinson, W. H. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment
Abstract Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases in childhood with a prevalence of 4 in 1,000 children. Anterior uveitis is a well-known threatening comorbid condition of JIA and affects around 10 % of the patients depending on JIA subtype. A large proportion of children with JIA develop uveitis in the first year of disease and 73 to 90 % after 4 years. Uveitis can progress into adulthood and usually occurs as ‘white uveitis’, while in the JIA related to the enthesitis subtype that is symptomatic. Current studies reinforced the previous observations that early age o...
Source: Clinical Reviews in Allergy and Immunology - November 22, 2015 Category: Allergy & Immunology Source Type: research